179 related articles for article (PubMed ID: 26308224)
1. Measurement of Metabolic Monitoring in Youth and Adult Medicaid Recipients Prescribed Antipsychotics.
Edelsohn GA; Parthasarathy M; Terhorst L; Karpov IO; Schuster J
J Manag Care Spec Pharm; 2015 Sep; 21(9):769-77, 777a-777cc. PubMed ID: 26308224
[TBL] [Abstract][Full Text] [Related]
2. Monitoring of Recommended Metabolic Laboratory Parameters Among Medicaid Recipients on Second-Generation Antipsychotics in Federally Qualified Health Centers.
Uzal NE; Chavez B; Kosirog ER; Billups SJ; Saseen JJ
Ann Pharmacother; 2018 Feb; 52(2):160-165. PubMed ID: 28884591
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Testing for Adults in a State Medicaid Program Receiving Antipsychotics: Remaining Barriers to Achieving Population Health Prevention Goals.
Morrato EH; Campagna EJ; Brewer SE; Dickinson LM; Thomas DS; Miller BF; Dearing J; Druss BG; Lindrooth RC
JAMA Psychiatry; 2016 Jul; 73(7):721-30. PubMed ID: 27167755
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data.
Morrato EH; Newcomer JW; Allen RR; Valuck RJ
J Clin Psychiatry; 2008 Feb; 69(2):316-22. PubMed ID: 18251625
[TBL] [Abstract][Full Text] [Related]
5. Quality of monitoring for metabolic effects associated with second generation antipsychotics in patients with schizophrenia on public insurance.
Moeller KE; Rigler SK; Mayorga A; Nazir N; Shireman TI
Schizophr Res; 2011 Mar; 126(1-3):117-23. PubMed ID: 21168994
[TBL] [Abstract][Full Text] [Related]
6. Metabolic Monitoring Rates of Youth Treated with Second-Generation Antipsychotics in Usual Care: Results of a Large US National Commercial Health Plan.
Hayden JD; Horter L; Parsons T; Ruble M; Townsend S; Klein CC; Duran RP; Welge JA; Crystal S; Patel NC; Correll CU; DelBello MP
J Child Adolesc Psychopharmacol; 2020 Mar; 30(2):119-122. PubMed ID: 31851522
[No Abstract] [Full Text] [Related]
7. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs.
Morrato EH; Druss B; Hartung DM; Valuck RJ; Allen R; Campagna E; Newcomer JW
Arch Gen Psychiatry; 2010 Jan; 67(1):17-24. PubMed ID: 20048219
[TBL] [Abstract][Full Text] [Related]
8. The effect of a computerized best practice alert system in an outpatient setting on metabolic monitoring in patients on second-generation antipsychotics.
Cohen S; Bostwick JR; Marshall VD; Kruse K; Dalack GW; Patel P
J Clin Pharm Ther; 2020 Dec; 45(6):1398-1404. PubMed ID: 32767599
[TBL] [Abstract][Full Text] [Related]
9. Child and adolescent psychiatrists' reported monitoring behaviors for second-generation antipsychotics.
Rodday AM; Parsons SK; Mankiw C; Correll CU; Robb AS; Zima BT; Saunders TS; Leslie LK
J Child Adolesc Psychopharmacol; 2015 May; 25(4):351-61. PubMed ID: 25918843
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a computer-based intervention to enhance metabolic monitoring in psychiatry inpatients treated with second-generation antipsychotics.
DelMonte MT; Bostwick JR; Bess JD; Dalack GW
J Clin Pharm Ther; 2012 Dec; 37(6):668-73. PubMed ID: 22845616
[TBL] [Abstract][Full Text] [Related]
11. Assessment of monitoring for glucose and lipid dysregulation in adult Medi-Cal patients newly started on antipsychotics.
Barnett M; VonMuenster S; Wehring H; Popish S; McDonald K; Walker VM; Perry P
Ann Clin Psychiatry; 2010 Feb; 22(1):9-18. PubMed ID: 20196978
[TBL] [Abstract][Full Text] [Related]
12. Advocacy for better metabolic monitoring after antipsychotic initiation: based on data from a French health insurance database.
Bulteau S; Le Pierres M; Artarit P; Forestier B; Michaud E; Chaslerie A; Bonnot O; Victorri-Vigneau C
Expert Opin Drug Saf; 2021 Feb; 20(2):225-233. PubMed ID: 33225754
[No Abstract] [Full Text] [Related]
13. Adherence to guidelines for glucose assessment in starting second-generation antipsychotics.
Raebel MA; Penfold R; McMahon AW; Reichman M; Shetterly S; Goodrich G; Andrade S; Correll CU; Gerhard T
Pediatrics; 2014 Nov; 134(5):e1308-14. PubMed ID: 25287454
[TBL] [Abstract][Full Text] [Related]
14. Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011.
Connolly JG; Toomey TJ; Schneeweiss MC
Psychiatr Serv; 2015 Jun; 66(6):604-9. PubMed ID: 25726977
[TBL] [Abstract][Full Text] [Related]
15. Age-dependent metabolic effects of second-generation antipsychotics in second-generation antipsychotic-naïve French Canadian patients.
Roy G; Bedard A; Desmarais PA; Jourdain F; Allen S; Michaud D; Ben Amor L
J Child Adolesc Psychopharmacol; 2010 Dec; 20(6):479-87. PubMed ID: 21186966
[TBL] [Abstract][Full Text] [Related]
16. Glucose monitoring in new users of second-generation antipsychotics in older people.
Ndukwe HC; Nishtala PS
Arch Gerontol Geriatr; 2017; 70():136-140. PubMed ID: 28131975
[TBL] [Abstract][Full Text] [Related]
17. Metabolic Monitoring of Child and Adolescent Patients on Atypical Antipsychotics by Psychiatrists and Primary Care Providers.
Wakefield S; Aligeti M; Rachamallu V; Baronia R; Aynampudi R; Parmar A; Peterson P; Masodkar K
Am J Ther; 2020; 27(5):e425-e430. PubMed ID: 30762589
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of Adverse Drug Reaction-Related Parameters in Children, Youth, and Young Adults Prescribed Antipsychotic Drugs by General Practitioners.
Minjon L; van den Ban E; Bazelier MT; Lalmohamed A; Egberts TCG; Heerdink ER
J Child Adolesc Psychopharmacol; 2022 Feb; 32(1):36-44. PubMed ID: 34619039
[No Abstract] [Full Text] [Related]
19. Trends in off-label use of antipsychotic medications among Texas Medicaid children and adolescents from 2013 to 2016.
Chen S; Barner JC; Cho E
J Manag Care Spec Pharm; 2021 Aug; 27(8):1035-1045. PubMed ID: 34337993
[No Abstract] [Full Text] [Related]
20. [Metabolic testing rates after initiation of antipsychotic treatment in persons initially treated by conventional mood-stabilizers].
Verdoux H; Gaudron Y; Auleley GR; Deligne J; Blum-Boisgard C; Thiébaut A; Tournier M
Encephale; 2013 May; 39 Suppl 1():S22-8. PubMed ID: 23246328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
